Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2016

21.07.2016 | Breast Oncology

Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery

verfasst von: Ted A. James, MD, MS, FACS, Alex R. Coffman, BS, Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FRCS(C), FACS, Judy C. Boughey, MD, FACS, V. Suzanne Klimberg, MD, Monica Morrow, MD, FACS, Armando E. Giuliano, MD, FACS, FRCSEd, Seth P. Harlow, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Performing a sentinel lymph node biopsy (SLNB) is the standard of care for axillary nodal staging in patients with invasive breast cancer and clinically negative nodes. The procedure provides valuable staging information with few complications when performed by experienced surgeons. However, variation in proficiency exists for this procedure, and a great amount of experience is required to master the technique, especially when faced with challenging cases. The purpose of this paper was to provide a troubleshooting guide for commonly encountered technical difficulties in SLNB, and offer potential solutions so that surgeons can improve their own technical performance from the collective knowledge of experienced specialists in the field.

Methods

Information was obtained from a convenience sample of six experienced breast cancer specialists, each actively involved in training surgeons and residents/fellows in SLNB. Each surgeon responded to a structured interview in order to provide salient points of the SLNB procedure.

Results

Four of the key opinion surgical specialists provided their perspective using technetium-99 m sulfur colloid, and two shared their experience using blue dye only. Distinct categories of commonly encountered problem scenarios were presented and agreed upon by the panel of surgeons. The responses to each of these scenarios were collected and organized into a troubleshooting guide.

Discussion

We present a compilation of ‘tips’ organized as a troubleshooting guide to be used to guide surgeons of varying levels of experience when encountering technical difficulties with SLNB.
Literatur
1.
Zurück zum Zitat Singletary S. Current status of axillary node dissection. Contemp Surg. 2002;58:334–340. Singletary S. Current status of axillary node dissection. Contemp Surg. 2002;58:334–340.
2.
Zurück zum Zitat Wong SL, Abell TD, Chao C, Edwards MJ, McMasters KM. Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: a decision analysis. Cancer. 2002;95(3):478–487.CrossRefPubMed Wong SL, Abell TD, Chao C, Edwards MJ, McMasters KM. Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: a decision analysis. Cancer. 2002;95(3):478–487.CrossRefPubMed
3.
Zurück zum Zitat Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391–398; discussion 398–401. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391–398; discussion 398–401.
4.
Zurück zum Zitat Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335–339; discussion 340. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335–339; discussion 340.
5.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933.CrossRefPubMedPubMedCentral Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100(7):462–474.CrossRefPubMed Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100(7):462–474.CrossRefPubMed
7.
Zurück zum Zitat Sanidas EE, de Bree E, Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am J Surg. 2003;185(3):202–210.CrossRefPubMed Sanidas EE, de Bree E, Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am J Surg. 2003;185(3):202–210.CrossRefPubMed
8.
Zurück zum Zitat Johnson JM, Orr RK, Moline SR. Institutional learning curve for sentinel node biopsy at a community teaching hospital. Am Surg. 2001;67(11):1030–1033.PubMed Johnson JM, Orr RK, Moline SR. Institutional learning curve for sentinel node biopsy at a community teaching hospital. Am Surg. 2001;67(11):1030–1033.PubMed
9.
Zurück zum Zitat Moonka R, Hunter JA, Cray WK, Duncan M, Wechter DG. A comparison of rates of lymph node metastases between patients undergoing sentinel and axillary lymphadenectomy. Am J Surg. 2002;183(5):558–561.CrossRefPubMed Moonka R, Hunter JA, Cray WK, Duncan M, Wechter DG. A comparison of rates of lymph node metastases between patients undergoing sentinel and axillary lymphadenectomy. Am J Surg. 2002;183(5):558–561.CrossRefPubMed
10.
Zurück zum Zitat Kiluk JV, Ly QP, Meade T, et al. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011;18(Suppl 3):S339–S342.CrossRefPubMed Kiluk JV, Ly QP, Meade T, et al. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011;18(Suppl 3):S339–S342.CrossRefPubMed
11.
Zurück zum Zitat Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339(14):941–946.CrossRefPubMed Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339(14):941–946.CrossRefPubMed
12.
Zurück zum Zitat Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001;193(6):593–600.CrossRefPubMed Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001;193(6):593–600.CrossRefPubMed
13.
Zurück zum Zitat Stitzenberg KB, Chang Y, Louie R, Groves JS, Durham D, Fraher EF. Improving our understanding of the surgical oncology workforce. Ann Surg. 2014;259(3):556–562.CrossRefPubMed Stitzenberg KB, Chang Y, Louie R, Groves JS, Durham D, Fraher EF. Improving our understanding of the surgical oncology workforce. Ann Surg. 2014;259(3):556–562.CrossRefPubMed
14.
Zurück zum Zitat Cady B, Falkenberry SS, Chung MA. The surgeon’s role in outcome in contemporary breast cancer. Surg Oncol Clin N Am. 2000;9(1):119–132.PubMed Cady B, Falkenberry SS, Chung MA. The surgeon’s role in outcome in contemporary breast cancer. Surg Oncol Clin N Am. 2000;9(1):119–132.PubMed
15.
Zurück zum Zitat Newman LA. Locoregional control of breast cancer: surgical technique does matter. Ann Surg Oncol. 2004;11(1):11–13.CrossRefPubMed Newman LA. Locoregional control of breast cancer: surgical technique does matter. Ann Surg Oncol. 2004;11(1):11–13.CrossRefPubMed
16.
Zurück zum Zitat Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the Consensus Conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94(10):2542–2551CrossRefPubMed Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the Consensus Conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94(10):2542–2551CrossRefPubMed
17.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461.CrossRefPubMedPubMedCentral Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104(4):692–699.CrossRefPubMed Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104(4):692–699.CrossRefPubMed
19.
Zurück zum Zitat Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500.CrossRefPubMed Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500.CrossRefPubMed
20.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–888.CrossRefPubMed Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–888.CrossRefPubMed
21.
Zurück zum Zitat Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189(2):236–239.CrossRefPubMed Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189(2):236–239.CrossRefPubMed
22.
Zurück zum Zitat Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol. 2009;99(6):356–360.CrossRefPubMed Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol. 2009;99(6):356–360.CrossRefPubMed
23.
Zurück zum Zitat Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc. 2008;100(12):1483–1484.CrossRefPubMed Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc. 2008;100(12):1483–1484.CrossRefPubMed
24.
Zurück zum Zitat Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg. 2008;196(2):228–233.CrossRefPubMed Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg. 2008;196(2):228–233.CrossRefPubMed
25.
Zurück zum Zitat Golshan M, Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J. 2006;12(5):428–430.CrossRefPubMed Golshan M, Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J. 2006;12(5):428–430.CrossRefPubMed
26.
Zurück zum Zitat Martin RC, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128(2):139–144.CrossRefPubMed Martin RC, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128(2):139–144.CrossRefPubMed
27.
Zurück zum Zitat Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol. 2008;15(10):2728–2733.CrossRefPubMed Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol. 2008;15(10):2728–2733.CrossRefPubMed
28.
Zurück zum Zitat McMasters KM, Wong SL, Martin RC, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg. 2001;233(5):676–687.CrossRefPubMedPubMedCentral McMasters KM, Wong SL, Martin RC, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg. 2001;233(5):676–687.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M. Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer. Br J Surg. 2015;102(3):169–181.CrossRefPubMed Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M. Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer. Br J Surg. 2015;102(3):169–181.CrossRefPubMed
30.
Zurück zum Zitat Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113(1):30–37.CrossRefPubMedPubMedCentral Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113(1):30–37.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park B-W. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14(4):296–300.CrossRefPubMedPubMedCentral Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park B-W. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14(4):296–300.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zakaria S, Degnim AC, Kleer CG, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol. 2007;96(7):554–559.CrossRefPubMed Zakaria S, Degnim AC, Kleer CG, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol. 2007;96(7):554–559.CrossRefPubMed
33.
Zurück zum Zitat Chagpar AB, Scoggins CR, Martin RCG, et al. Are 3 sentinel nodes sufficient? Arch Surg Chic III 1960. 2007;142(5):456–459; discussion 459–460. Chagpar AB, Scoggins CR, Martin RCG, et al. Are 3 sentinel nodes sufficient? Arch Surg Chic III 1960. 2007;142(5):456–459; discussion 459–460.
34.
Zurück zum Zitat Chagpar A, Martin RC, Chao C, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg. 2004;139(6):614–618; discussion 618–620. Chagpar A, Martin RC, Chao C, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg. 2004;139(6):614–618; discussion 618–620.
35.
Zurück zum Zitat Manca G, Volterrani D, Mazzarri S, et al. Sentinel lymph node mapping in breast cancer: a critical reappraisal of the internal mammary chain issue. Q J Nucl Med Mol Imaging. 2014;58(2):114–126.PubMed Manca G, Volterrani D, Mazzarri S, et al. Sentinel lymph node mapping in breast cancer: a critical reappraisal of the internal mammary chain issue. Q J Nucl Med Mol Imaging. 2014;58(2):114–126.PubMed
36.
Zurück zum Zitat Mansel RE, Goyal A, Newcombe RG; ALMANAC Trialists Group. Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin Breast Cancer. 2004;5(4):279–284; discussion 285–286. Mansel RE, Goyal A, Newcombe RG; ALMANAC Trialists Group. Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin Breast Cancer. 2004;5(4):279–284; discussion 285–286.
37.
Zurück zum Zitat Chagpar AB, Kehdy F, Scoggins CR, et al. Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. Am J Surg. 2005;190(4):557–562.CrossRefPubMed Chagpar AB, Kehdy F, Scoggins CR, et al. Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. Am J Surg. 2005;190(4):557–562.CrossRefPubMed
38.
Zurück zum Zitat Harlow S, Krag D, Weaver D, Ashikaga T. Extra-axillary sentinel lymph nodes in breast cancer. Breast Cancer. 1999;6(2):159–165.CrossRefPubMed Harlow S, Krag D, Weaver D, Ashikaga T. Extra-axillary sentinel lymph nodes in breast cancer. Breast Cancer. 1999;6(2):159–165.CrossRefPubMed
39.
Zurück zum Zitat Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242(4):593–599; discussion 599–602. Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242(4):593–599; discussion 599–602.
Metadaten
Titel
Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery
verfasst von
Ted A. James, MD, MS, FACS
Alex R. Coffman, BS
Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FRCS(C), FACS
Judy C. Boughey, MD, FACS
V. Suzanne Klimberg, MD
Monica Morrow, MD, FACS
Armando E. Giuliano, MD, FACS, FRCSEd
Seth P. Harlow, MD
Publikationsdatum
21.07.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5432-8

Weitere Artikel der Ausgabe 11/2016

Annals of Surgical Oncology 11/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.